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Robust IGF-I overexpression induces ocular angiogenesis in mice. To investigate the eﬀect of subtle IGF-I overexpression, we exam-
ined the ocular phenotype of IGF-II promoter-driven IGF-I transgenic mice. Despite 2.5-fold elevation of IGF-I mRNA in the retina
and 29 and 52% increase of IGF-I protein in the retina and aqueous humor, respectively, no ocular abnormality was observed in these
transgenics. This was correlated with unaltered VEGF mRNA levels in the transgenic retina. The transgene was also associated with an
attenuated laser-induced choroidal neovascularization. Diﬀerential expression levels and pattern of IGF-I gene may underlie the diﬀerent
retinal phenotypes in diﬀerent transgenic lines.
Published by Elsevier Ltd.
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Neovascular age-related macular degeneration and pro-
liferative diabetic retinopathy, characterized by choroidal
neovascularization (CNV) or retinal neovascularization
(RNV), are the leading causes of blindness in the developed
countries. Due to the limited knowledge of the mechanisms
underlies these diseases, current treatments, like laser pho-
tocoagulation and anti-angiogenic agents, provide only
temporary or partial protection. Much eﬀort has been
devoted to determining the pathogenesis of neovasculariza-
tion and establishing reproducible animal models to assay
new treatments.
Insulin-like growth factor (IGF)-I has been associated
with the pathological ocular angiogenesis (Burgos et al.,0042-6989/$ - see front matter Published by Elsevier Ltd.
doi:10.1016/j.visres.2006.11.021
* Corresponding author. Fax: +1 317 274 1288.
E-mail address: xqiao@iupui.edu (X. Qiao).2000; Grant et al., 1993; Lambooij et al., 2003; Smith et al.,
1999). There is evidence that IGF-I can act directly as an
angiogenic factor on retinal and choriocapillary endothelial
cells (Grant, Caballero, &Millard, 1993; Spraul, Baldysiak-
Figiel, Lang, & Lang, 2002), and indirectly through the
induction of VEGF expression in retinal pigment epithelium
(RPE) cells and glial cells (Miele, Rochford, Filippa, Giorg-
etti-Peraldi, & Van Obberghen, 2000; Punglia et al., 1997;
Ruberte et al., 2004; Slomiany & Rosenzweig, 2004a,
2004b). Increased ocular levels of IGF-I in transgenic mice
driven by an insulin promoter-I (Insulin/IGF-I transgenic
mice) have been reported to result in a condition similar to
diabetic retinopathy (Ruberte et al., 2004). A role of IGF-I
in vessel formation and remodelling also is suggested by
abnormal retinal vascular growth in the IGF-I knockout
mice, despite the presence of VEGF (Hellstrom et al.,
2001). Furthermore, abundant evidence indicates that
IGF-I protects a variety of ocular cells from metabolic and
ischemic damage (Bridgewater, Ho, Sauro, & Matsell,
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Zhong et al., 2005). IGF-I prevents the degeneration of reti-
nal amacrine cells in culture (Politi, Rotstein, Salvador, Giu-
sto, & Insua, 2001) and R28 retinal precursor cells (Seigel,
Chiu, & Paxhia, 2000). In the rat retina, IGF-I protects axo-
tomized retinal ganglion cells from secondary cell death
(Kermer, Klocker, Labes, & Bahr, 2000), and prevents cell
death under in vitro conditions of hypoxia or serum-starva-
tion (Seigel et al., 2000).
Several lines of IGF-I transgenic mice under diﬀerent
promoters have been generated to date (Ruberte et al.,
2004; Ye, Carson, & D’Ercole, 1995a, Ye, Carson, &
D’Ercole, 1995b; Ye, Lee, & D’Ercole, 2000; Ye, Xing,
Dai, & D’Ercole, 1996). Characterization of these transgen-
ics revealed diﬀerential phenotypes in the brain as well as
other peripheral organs. However, except diabetes-like ret-
inopathy in the line of Insulin/IGF-I transgenic, the ocular
eﬀects of altered IGF-I expression in the other lines are not
known. It is not clear whether overexpression of IGF-I in
the eye is always associated with ocular pathology. A line
of transgenic mice overexpressing IGF-I driven by an
IGF-II promoter (IGF-II/IGF-I transgenic mice) is fea-
tured with signiﬁcant transgene expression only in the cen-
tral nervous system (CNS) with particularly high level in the
cerebellum (Ye et al., 1996; Zhong et al., 2005). As retina is
part of nervous system and IGF-II is expressed in the retina
(Arnold et al., 1993), an increased level of IGF-I is expected
in the retina of IGF-II/IGF-I mice. Therefore, in the pres-
ent study, we characterized the ocular phenotype and exam-
ined the expression patterns of IGF-I and VEGF in the
retina of the transgenic mice. Potential eﬀects of IGF-I
overexpression on the formation of CNV induced by laser
photocoagulation (Lambert et al., 2003; Ming et al., 2004;
Sakurai, Anand, Ambati, van Rooijen, & Ambati, 2003;
Silva et al., 2005; Tobe et al., 1998) were also investigated.
2. Materials and methods
2.1. Animals
Fourteen pairs of adult IGF-II/IGF-I transgenic mice and their age
and sex matched wildtype littermates were used in the study. Generation
of the IGF-II/IGF-I transgenic mice and determination of the genotype
has been described previously (Ye et al., 1996; Zhong et al., 2005). Brieﬂy,
these transgenic mice carry a 6.9 kb fusion gene with a 5.7 kb fragment of
the 5 0 mouse IGF-II genomic regulatory region driving the expression of a
human IGF-I cDNA. Mice were subject for PCR genotyping of IGF-I
transgene using tail genomic DNA.
All animals were maintained on a 12/12 h (light/dark) cycle at 22 C,
and were provided access to water and diet ad libitum. All procedures
were performed with strict adherence to the guidelines for animal care
and experimentation prepared by the Association for Research in Vision
and Ophthalmology and approved by the Indiana University Animal Care
and Use Committee.
2.2. Slit-lamp microscopy, fundus photography and ﬂuorescein
angiography
Mice were anesthetized using Avertin 0.02 ml/gm body weight (1.25%
w/v tribromoethanol, 0.8% v/v amyl alcohol). Topical 1% tropicamide
and 2.5% phenylephrine were administered for pupillary dilation. Beforelaser photocoagulation and eye enucleation, all mice were examined under
slit-lamp microscopy, fundus photography and ﬂuorescein angiography
(FA). For FA evaluations, 25% sodium ﬂuorescein (0.1 mg/kg) was
administered intraperitoneally. Individual lesion sites, photographed dur-
ing late phase ﬂuorescein angiography, were subjected to analysis for the
presence and intensity of staining and leakage using the murine FA leak-
age score (0 ‘‘no leakage’’ to 3 ‘‘strong leakage’’) as reported previously
(Hu et al., 2005; Takahashi, Kishi, Muraoka, & Shimizu, 1998).
2.3. Laser photocoagulation to induce CNV
Five pairs of IGF-I transgenics and their wildtype littermates received
laser photocoagulation at 3 and half months of age. After pupillary dila-
tion, anesthetized animals were positioned before a slit-lamp (Carl Zeiss
Meditec, Jena, Germany) laser-delivery system. The fundus was visualized
using a cover slip with 2.5% hydroxypropyl methylcellulose solution
(Goniosol) as an optical coupling agent. A diode laser (OcuLight GL, Iris
Medical Instrument, Inc., Mountain View, CA) was used for photocoag-
ulation (532 nm wavelength, 0.05 s duration, 75 lm spot size and 120 mW
power), which most reliably produced acute vapor bubble, suggestive of
Bruch’s membrane rupture (Hu et al., 2005; Lambert et al., 2003; Tobe
et al., 1998). In all experiments, a series of four photocoagulation sites
were concentrically placed at equal distances (75–100 lm) around the
optic disk in each eye. Two weeks after laser photocoagulation, when
CNV was well established (Tobe et al., 1998) and reached maximum size
(Espinosa-Heidmann et al., 2002), eyes were processed for histological
analysis.
2.4. Quantitative real-time RT-PCR
Total RNA was isolated from retinal tissues of the left eye in two pairs
of IGF-II/IGF-I transgenic mice and their wildtype littermates at 4
months of age, using RNeasy Mini Kit (Qiagen, Valencia, California) fol-
lowing the manufacturer’s protocol. Quantitative real-time RT-PCR, after
reverse transcription, was performed to determine the gene expression lev-
els of IGF-I and VEGF. Brieﬂy, 1 lg total RNA was used for the ﬁrst-
strand cDNA synthesis (SuperScript II reverse transcriptase; Invitrogen,
Carlsbad, CA) with Oligo(dT)12–18 primer (Invitrogen) according to the
manufacturer’s instructions. Real-time PCR was performed in triplicate
using 25 ll of reaction mixture containing primer, cDNA, and iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA) on a single-color real-time
PCR detection system (MyiQ; Bio-Rad). Reactions were started with
denaturing at 94 C for 5 min and followed by 40 cycles of denaturing
at 94 C for 30 s, annealing and extending at 60 C for 45 s. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was used as the reference
gene, and relative levels of IGF-I and VEGF compared with that of GAP-
DH were calculated.
The sequences of speciﬁc primers are listed as follows. Mouse GAP-
DH: 5 0-TCC TGG TAT GAC AAT GAA TAC GGC-3 0 (forward) and
5 0-TCT TGC TCA GTG TCC TTG CTG G-30 (reverse). Mouse IGF-I:
5 0-TTC ACA TCT CTT CTA CCT GGC-3 0 (forward) and 5 0-TCT
TGT TTC CTG CAC TTC CT-30 (reverse). Transgene (human IGF-I):
5 0-GGA CCG GAG ACG CTC TGC GG-3 0 (forward) and 5 0-CTG
CGG TGG CAT GTC ACT CT-30 (reverse). Mouse VEGF: 5 0-AGG
CTG CAC CCA CGA CAG AA-3 0 (forward) and 5 0-CTT TGG TCT
GCA TTC ACA TC-30 (reverse).
2.5. In situ hybridization
Right eyes of six pairs of mice at 2, 4 and 10 months of age were ﬁxed
in 4% phosphate-buﬀered paraformaldehyde solution overnight at 4 C.
Tissues were dehydrated, embedded in paraﬃn, serially sectioned
(6 lm). Standard protocols of riboprobe in situ hybridization were fol-
lowed as described in detail previously (Gao, Qiao, Hefti, Hollyﬁeld, &
Knusel, 1997; Qiao, Hefti, Knusel, & Noebels, 1996). A human IGF-I
cDNA clone consisting of 369 bp coding region and a 570 bp mouse
VEGF cDNA clone in pBluescript SK plasmid obtained as a generous gift
Fig. 1. Quantitative real-time RT-PCR of IGF-I and VEGF mRNAs in
the retina of IGF-II/IGF-I transgenic (T) and wildtype (W) mice at 4
months of age. The endogenous mouse IGF-I (mIGF-I) level was not
signiﬁcantly altered in the transgenic mice comparing to that in the
wildtype. High levels of human IGF-I transgene (hIGF-I) were detected in
the transgenic but not in the wildtype retina. The sum of the ratio of total
IGF-I over GAPDH signals, including transgenic and endogenous IGF-I,
in the transgenic retina was 2.5-fold of that in the wildtype. There was no
signiﬁcant diﬀerence in the VEGF/GAPDH ratio between the transgenic
and the wildtype mice.
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Nawaz, Chiappetta, & Stancel, 2000) were used to generate riboprobes.
35S-labeled riboprobes were transcribed using Riboprobe Gemini System
according to manufacturer’s instructions (Promega Inc., Madison, WI).
The tissue sections were deparaﬃnized in xylene followed by rehydration.
The sections were pretreated with 10 mg/ml proteinase K at 37 C for
20 min, and then 0.25% acetic anhydrite in 0.1 M triethanolamide for
10 min. The sections were incubated at 50 C on a slide warmer overnight
with a probe solution containing 5 · 106 cpm/ml 35S-labeled probes, 50%
formamide, 10% dextran sulfate, 300 mM NaCl, 0.5 mg/ml tRNA,
10 mM DTT, 0.02% Ficoll, 0.02% polyvinyl-pyrolidone, 0.02% BSA and
1 mM EDTA in 10 mM Tris–HCl (pH 8.0). Following hybridization,
the slides were rinsed in 4· SSC (150 mM NaCl and 15 mM sodium cit-
rate), digested with 20 lg/ml RNase A at 37 C for 30 min, washed
through descending concentrations of SSC to 0.1· SSC at 60–70 C.
The slides were then dehydrated, dried and coated with NTB-2 emulsion
(Kodak Inc., Rochester, NY). Following exposure in the dark for 4 weeks,
the emulsion was developed and sections were counter-stained with
hematoxylin.
2.6. Radioimmunoassay of IGF-I
Retinal tissues of six pairs of eyes were homogenized in ice cold lysis
buﬀer containing 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS),
1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, 1 lg/ml aprotinin, 1 lg/ml leu-
peptin, 1 lg/ml pepstatin and 50 mM Tris–HCl, pH 7.4. The suspension
was centrifuged at 10,000 rpm for 30 min at 4 C and the supernatant
was removed for protein concentration measurement by a Bio-Rad pro-
tein assay kit. Total IGF-I concentrations in the retina and in aqueous
humor were determined by radioimmunoassay (RIA) (ALPCO Diagnos-
tics, Windham, NH) using the standard procedure suggested by the man-
ufacturer, in which special sample preparation is not required before
measurement. The sensitivity of the assay is 0.02 ng/ml. The concentration
in the retina was expressed as ng/mg total protein.
2.7. Histology and CNV assessment
Serial, radial tissue sections through each recovered lesion site were
evaluated in their entirety to quantify the extent of ﬁbrovascular prolifer-
ation. For statistical analyses, maximum CNV membrane thickness mea-
surement, which typically occurred at or near the center of the initial
trauma site, were obtained from digital photographs (Nikon CoolPix
990 modiﬁed camera system) and then were converted to lm measure-
ments (using graticule image measurements for comparison). As reported
previously (Ciulla et al., 2003), this technique demonstrated reproducibil-
ity of measurements within ±2 lm using a random sampling of represen-
tative masked lesions. CNV membrane mean thickness values for
each group were obtained using the maximum thickness measurements
of each of the four lesion sites per eye to then determine an average value
for each site within IGF-I transgenic mice and from wildtype mice. The
values were expressed as means ± standard deviation (SD).
2.8. Statistical analysis
The Student’s t-test was used to compare the diﬀerences of CNV mem-
brane mean thickness and FA leakage mean score between the transgenic
and wildtype groups. p values of less than 0.05 were considered to be
signiﬁcant.
3. Results
3.1. No spontaneous ocular neovascularization in the IGF-I
transgenic mice
Slit-lamp microscopy revealed no evidence of cornea or
iris neovascularization or of cataracts in the IGF-II/IGF-Itransgenic mice at any age up to 10 months. On funduscop-
ic examination no retinal hemorrhage or vessel dilatation
was noticed. Fluorescein angiography did not reveal any
leakage before laser photocoagulation, suggesting that no
spontaneous RNV or CNV occurred. Histologically,
no abnormality of ocular morphology was noticed and
no spontaneous retinal/choroidal neovascularization was
observed at ages up to 10 months (image not presented).3.2. Signiﬁcant overexpression of IGF-I mRNA in the
transgenic retina
To conﬁrm that IGF-I is overexpressed in the retina, the
levels of IGF-ImRNAweremeasured by both real-timeRT-
PCR and in situ hybridization. As shown in Fig. 1, the levels
of endogenous mouse IGF-I mRNA between the transgenic
and wildtype groups were not signiﬁcantly diﬀerent
(p > 0.05). Signiﬁcant expression of the human IGF-I trans-
gene was detected in the transgenic but not in the wildtype
retina. As the ampliﬁcation eﬃciency in two sets of reactions
may not be exactly same, we can only estimate the total
amount of IGF-I mRNA after standardized with the inter-
nal controlmoleculeGAPDH.The sumof the IGF-ImRNA
ratio in the transgenic retina, including transgenic and
endogenous IGF-I, was 2.5-fold of that in the wildtype. In
situ hybridization demonstrated that the increased signals
of IGF-I mRNA in the transgenics were predominantly
concentrated in the ganglion cell layer and inner segment
of photoreceptors (Fig. 2). This overexpression was evident
at all ages studied (2, 4 and 10 months of age).3.3. No upregulation of VEGF mRNA in the transgenic
retina
Because IGF-I has been suggested to mediate patholog-
ical angiogenesis through induction of VEGF expression in
Fig. 2. In situ hybridization of the expression pattern of IGF-I mRNA in the adult IGF-II/IGF-I transgenic and wildtype mice. IGF-I mRNA was
increased in the transgenic retina at 2, 4 and 10 months of age (images showed at 4 months of age). The increased signals, shown as bright clusters (pointed
by arrows in the left panel) in the dark-ﬁeld images, were located mainly in the ganglion cell layer and inner segment of photoreceptor. GCL, ganglion cell
layer; INL, inner nuclear layer; ONL, outer nuclear layer; ISP, inner segment of photoreceptor.
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assessed by real-time RT-PCR and in situ hybridization in
the retina of IGF-II/IGF-I transgenic mice. Real-time RT-
PCR revealed similar levels of VEGF mRNA in the retina
of transgenic and wildtype at 4 months of age without sta-
tistic diﬀerence (p > 0.05). The pattern of VEGF mRNA in
the transgenic retina mapped by in situ hybridization was
also not diﬀerent from that in the wildtype (image not pre-
sented). The results are consistent with lack of spontaneous
angiogenesis in the retina of this mutant line.Fig. 3. Radioimmunoassay of IGF-I levels in the retina and aqueous
humor at 4 months of age. Compared to the wildtype, IGF-I concentra-
tion has an increase of 29% in the transgenic retina and 52% in the3.4. Moderate increase of IGF-I concentration in the
transgenic retina and aqueous humor
The expression of IGF-I protein was conﬁrmed by
radioimmunoassay. As shown in Fig. 3, the IGF-I concen-
tration had an increase of 29% in the transgenic retina
(4.61 ± 0.35 ng/mg total protein) when compared to that
in the wildtype (3.57 ± 0.11 ng/mg total protein). The
increase of IGF-I protein level was even higher in the trans-
genic aqueous humor (9.44 ± 0.33 ng/ml) 52% more than
that in the wildtype (6.20 ± 1.87 ng/ml).transgenic aqueous humor (six pairs of eyes).3.5. Less CNV membranes induced in the transgenic mice
To determine if overexpression of IGF-I may facilitate
lesion-trigged angiogenic response, laser photocoagulation
model was used to induce choroidal neovascularization.
FA examination 2 weeks after the laser treatment revealed
less subretinal ﬂuorescein leakage at the laser sites in the
transgenic mice than that in the wildtype (Fig. 4). Quanti-
tative analysis of ﬂuorescein leakage was statistically signif-
icant with lower FA score at the lesion sites in the
transgenic mice (mean FA score of 1.8 ± 0.8) than that in
the wildtype mice (mean score 2.2 ± 0.8; p < 0.05).
Histologically, the CNV membrane was well established
in 2 weeks after laser photocoagulation. The dome-shaped
CNV membrane contained ﬁbrovascular tissue with ves-
sels, scattered RPE cells, and macrophage-like cells. Mor-phologic features of CNV membranes in the transgenic
mice were comparable to those in the wildtype mice
(Fig. 5). Quantitative histopathologic analysis demonstrat-
ed that the mean CNV membrane thickness of 40 laser sites
was signiﬁcantly thinner in the transgenic (48.9 ± 17.8 lm)
than that in the wildtype (62.7 ± 22.9 lm; p = 0.01). The
results indicate an attenuated, rather than intensiﬁed
lesion-induced angiogenic response in the IGF-II/IGF-I
transgenic mice, which does not support any facilitative
role of IGF-I in this model of CNV pathogenesis.
4. Discussion
In this line of IGF-I transgenic mice, the overexpression
of IGF-I is localized predominantly to the retinal ganglion
Fig. 4. Fluorescein angiography at 2 weeks after laser photocoagulation in the retina of transgenic (A) and wildtype (B) mice. The transgenics had less
ﬂuorescein leakage with a mean score of 1.8, versus 2.2 in the wildtype mice (40 laser sites of each group). (A) Scored as 0, 2, 1, 2 from 1 o’clock to 12
o’clock. (B) Scored as 3, 3, 3, 3.
Fig. 5. Choroidal neovascular membranes developed in the IGF-II/IGF-I transgenic mice and their wildtype littermates in 2 weeks after laser
photocoagulation. The membrane was morphologically comparable in both groups. The thickness of choroidal neovascular membrane showed above was
50 lm (transgenic) and 57 lm (wildtype). The mean thickness of membranes was 22% thinner in the transgenic mice than that in the wildtype mice (40 laser
sites in each group). Scale bar: 50 lm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
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signiﬁcant elevation of IGF-I mRNA levels in the eyes of
transgenic mice, no spontaneous neovascularization in cor-
nea, iris, retina or choroid was observed up to 10 months of
age. These results are diﬀerent from the Insulin/IGF-I
transgenic mouse reported by Ruberte et al. (2004), in
which the increased ocular levels of IGF-I lead to diabe-
tes-like eye disease.
Several possibilities may explain the diﬀerences between
these two lines of IGF-I transgenic mice. Diﬀerent promot-
ers drive these transgenes and lead to diﬀerent sites of IGF-
I overexpression in the retina. In IGF-II/IGF-I transgenic
mice, IGF-I mRNA is predominantly overexpressed at
ganglion cell layer and inner segment of photoreceptor,
while the Insulin/IGF-I transgenic mice, IGF-I is expressed
in the outer plexiform layer and in the inner segment of
photoreceptors. The diﬀerent locations of the IGF-I over-
expression could inﬂuence the local availability of IGF-I,
and result in diﬀerent phenotypes. Another explanation is
the magnitude of IGF-I overexpression in the two trans-
genic lines. IGF-II/IGF-I transgenic mice only showed
moderate overexpression of IGF-I in the retina and aque-ous humor, while in the Insulin/IGF-I transgenic mice,
the levels of IGF-I in the retina and aqueous humor were
ten to a 100-folds higher than those in the wildtype mice.
Danis et al. reported that diﬀerent intravitreous IGF-I lev-
els induced diﬀerent ocular changes, with larger doses pro-
ducing a retinal microangiopathy, while lower doses
showed fewer clinical and histopathologic changes (Danis
& Bingaman, 1997). It is highly possible that diﬀerent ocu-
lar IGF-I expression levels may dictate the extent of ocular
changes. Finally, there was no signiﬁcant upregulation of
VEGF observed in the IGF-II/IGF-I transgenic retina,
while a 2-fold increase of VEGF transcripts was detected
in the Insulin/IGF-I transgenic eyes. This could be the
most important and most direct cause for the diﬀerent ocu-
lar phenotypes between the two transgenic lines.
Interestingly, our data clearly showed that the IGF-II/
IGF-I transgenic mice developed less CNV membranes
and ﬂuorescein leakage following laser treatment than their
wildtype littermates. IGF-I has well documented anti-ap-
optotic actions on many cell types (Bridgewater et al.,
2005; Ozen et al., 2005; Popken et al., 2004; Song et al.,
2005; Zhong et al., 2005), including retinal precursor cells,
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apoptosis after laser-trauma attenuated the formation of
CNV. In addition, IGF-I bioactivity is inﬂuence by many
factor, such as the presence of IGF binding proteins
(IGFBPs) and the magnitude of IGF receptor expression
(Clemmons, 1998; Delafontaine, Song, & Li, 2004), which
is responsible for mediating most of IGF-I action. It has
been reported that granule neurons in the cerebellum of
IGF-II/IGF-I transgenic mice express high levels of IGF
binding protein 5, which has the capacity to block some
IGF-I activities (Zhong et al., 2005). It is possible, there-
fore, IGFBPs aﬀect IGF-I bioactivities and alter the overall
outcome in any speciﬁc cellular location. Additional exper-
iments are necessary to determine the underlying mecha-
nisms for the attenuated response of laser-induced CNV
in this transgenic mouse model.
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